Time To Antipsychotic Discontinuation After Remission Among Patients With Major Depressive Disorder With Psychotic Features At Tikur Anbessa Specialized Hospital: A Cross-Sectional Study.

dc.contributor.advisorDr. Getahun Belay
dc.contributor.advisorProfessor Solomon Teferra
dc.contributor.authorAssamin Assafaw
dc.date.accessioned2026-11-13T13:12:32Z
dc.date.available2026-11-13T13:12:32Z
dc.date.issued2026
dc.description.abstractBackground: Major depressive disorder with psychotic features is a severe and disabling condition that requires both antidepressant and antipsychotic treatment. Most international guidelines recommend maintaining antipsychotics for 4-6 months after clinical remission, but data on actual duration and discontinuation practices in our setting is limited for major depressive disorder with psychotic feature treatment. Objective: The objective of this study is to determine the time to antipsychotic discontinuation after remission among patients with major depressive disorder with psychotic features at Tikur Anbessa Specialized Hospital, 2025. Methods: A retrospective cross-sectional study was conducted among cases with major depressive disorder at TASH who had a follow-up for the past 5 years. Census method was used to select eligible patient records from the psychiatry follow-up EMR registry. Data on demographics, clinical profiles, antipsychotic treatment duration, remission, and discontinuation status was collected. Descriptive statistics was used to summarize the data and chi-square test to measure the association between categorical variables and results were presented using tables, graphs and charts. Result: A total of 234 MDD patients were included in the study with a mean (±SD) age of 39.6 ± 14.6 years, of whom 60 (25.6%) had MDD with psychotic features, and 62 (60 MDD-PF + 2 MDD as augmentation) patients initiated antipsychotic treatment, with risperidone, 58.3% and olanzapine, 25% being the most commonly prescribed. Clinical remission was achieved in 56.4% patients receiving antipsychotics. Prolonged antipsychotic treatment was found in 65.7% patient, and 48.6% patients still continued antipsychotic treatment following remission for a mean duration of 16.2 months (median: 15.5 months, IQR:9.4 months). Comorbid medical illness was the only factor significantly associated with remission (p = 0.011). Conclusion: The findings provide evidence on rational antipsychotics use and treatment practices for patients with major depressive disorder with psychotic features who start treatment at tertiary care setting. It supports the need to develop an institutionalized or national treatment protocol; help to improve psychiatric care while Vreducing the unnecessary prolonged antipsychotics use to ease the burden on both patients and the healthcare system
dc.identifier.urihttps://etd.aau.edu.et/handle/123456789/9602
dc.language.isoen
dc.publisherAddis Ababa Uinverstiy
dc.subjectMajor depressive disorder
dc.subjectPsychotic features
dc.subjectTime to antipsychotic discontinuation
dc.subjectclinical remission
dc.subjectEthiopia.
dc.titleTime To Antipsychotic Discontinuation After Remission Among Patients With Major Depressive Disorder With Psychotic Features At Tikur Anbessa Specialized Hospital: A Cross-Sectional Study.
dc.typeThesis

Files

Original bundle
Now showing 1 - 2 of 2
No Thumbnail Available
Name:
Alemu Gemeda 2025-etd pdf.pdf
Size:
1.02 MB
Format:
Adobe Portable Document Format
No Thumbnail Available
Name:
Assamin_ Assafaw_2026.pdf
Size:
915.36 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:

Collections